Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".
Bengt Rasmussen, Gudrun Göhring, Elsa Bernard, Lars Nilsson, Magnus Tobiasson, Martin Jädersten, Hege Garelius, Ingunn Dybedal, Kirsten Grønbaek, Elisabeth Ejerblad, Fryderyk Lorenz, Max Flogegård, Claus Werenberg Marcher, Annette Öster Fernström, Lucia Cavelier, Elli Papaemmanuil, Freja Ebeling, Astrid Olsnes Kittang, Jan Maxwell Nørgaard, Leonie Saft, Lars Möllgård, Eva Hellström-Lindberg
Leukemia 2022 MayNo abstract available.
Citation
Bengt Rasmussen, Gudrun Göhring, Elsa Bernard, Lars Nilsson, Magnus Tobiasson, Martin Jädersten, Hege Garelius, Ingunn Dybedal, Kirsten Grønbaek, Elisabeth Ejerblad, Fryderyk Lorenz, Max Flogegård, Claus Werenberg Marcher, Annette Öster Fernström, Lucia Cavelier, Elli Papaemmanuil, Freja Ebeling, Astrid Olsnes Kittang, Jan Maxwell Nørgaard, Leonie Saft, Lars Möllgård, Eva Hellström-Lindberg. Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)". Leukemia. 2022 May;36(5):1436-1439
Mesh Tags
Substances
PMID: 35277655
View Full Text
